BACKGROUND: Overlapping phenotypes including LHON, MELAS, and Leigh syndrome have recently been associated with numerous mtDNA point mutations in the ND5 gene of complex I, now considered a mutational hot spot. OBJECTIVE: To identify the mtDNA defect in a family with a prevalent ocular phenotype, including LHON-like optic neuropathy, retinopathy, and cataract, but characterised also by strokes, early deaths, and miscarriages on the maternal line. RESULTS: Sequencing of the entire mitochondrial genome from the proband's muscle DNA identified the heteroplasmic 13042G-->A transition, which was previously described only once in a patient with a different mitochondrial disease. This mutation fulfils the major pathogenic criteria, inducing an amino acid change (A236T) at an invariant position in a highly conserved domain of the ND5 gene. Phosphorus magnetic resonance spectroscopy in the proband disclosed an in vivo brain and skeletal muscle energy metabolism deficit. CONCLUSIONS: These findings conclusively establish the pathogenic role of the 13042G-->A mutation and underscore its variable clinical expression.
BACKGROUND: Overlapping phenotypes including LHON, MELAS, and Leigh syndrome have recently been associated with numerous mtDNA point mutations in the ND5 gene of complex I, now considered a mutational hot spot. OBJECTIVE: To identify the mtDNA defect in a family with a prevalent ocular phenotype, including LHON-like optic neuropathy, retinopathy, and cataract, but characterised also by strokes, early deaths, and miscarriages on the maternal line. RESULTS: Sequencing of the entire mitochondrial genome from the proband's muscle DNA identified the heteroplasmic 13042G-->A transition, which was previously described only once in a patient with a different mitochondrial disease. This mutation fulfils the major pathogenic criteria, inducing an amino acid change (A236T) at an invariant position in a highly conserved domain of the ND5 gene. Phosphorus magnetic resonance spectroscopy in the proband disclosed an in vivo brain and skeletal muscle energy metabolism deficit. CONCLUSIONS: These findings conclusively establish the pathogenic role of the 13042G-->A mutation and underscore its variable clinical expression.
Authors: Denise M Kirby; Avihu Boneh; C W Chow; Akira Ohtake; Michael T Ryan; Dominic Thyagarajan; David R Thorburn Journal: Ann Neurol Date: 2003-10 Impact factor: 10.422
Authors: V Petruzzella; G Di Giacinto; S Scacco; F Piemonte; A Torraco; R Carrozzo; R Vergari; C Dionisi-Vici; D Longo; A Tessa; S Papa; E Bertini Journal: Neurology Date: 2003-10-14 Impact factor: 9.910
Authors: M Chol; S Lebon; P Bénit; D Chretien; P de Lonlay; A Goldenberg; S Odent; L Hertz-Pannier; C Vincent-Delorme; V Cormier-Daire; P Rustin; A Rötig; A Munnich Journal: J Med Genet Date: 2003-03 Impact factor: 6.318
Authors: A Torroni; C Rengo; V Guida; F Cruciani; D Sellitto; A Coppa; F L Calderon; B Simionati; G Valle; M Richards; V Macaulay; R Scozzari Journal: Am J Hum Genet Date: 2001-10-10 Impact factor: 11.025
Authors: Byung-Ok Choi; Jung Hee Hwang; Joonki Kim; Eun Min Cho; Sun Young Cho; Su Jin Hwang; Hyang Woon Lee; Song Ja Kim; Ki Wha Chung Journal: Exp Mol Med Date: 2008-06-30 Impact factor: 8.718
Authors: Martin Engvall; Aki Kawasaki; Valerio Carelli; Rolf Wibom; Helene Bruhn; Nicole Lesko; Florian A Schober; Anna Wredenberg; Anna Wedell; Frank Träisk Journal: Front Neurol Date: 2021-03-25 Impact factor: 4.003